Literature DB >> 30226101

Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.

Fionn Woodcock1,2, Brett Doble1,2.   

Abstract

OBJECTIVES: To assess the external validity of mapping algorithms for predicting EQ-5D-3L utility values from EORTC QLQ-C30 responses not previously validated and to assess whether statistical models not previously applied are better suited for mapping the EORTC QLQ-C30 to the EQ-5D-3L.
METHODS: In total, 3866 observations for 1719 patients from a longitudinal study (Cancer 2015) were used to validate existing algorithms. Predictive accuracy was compared to previously validated algorithms using root mean squared error, mean absolute error across the EQ-5D-3L range, and for 10 tumor-type specific samples as well as using differences between estimated quality-adjusted life years. Thirteen new algorithms were estimated using a subset of the Cancer 2015 data (3203 observations for 1419 patients) applying various linear, response mapping, beta, and mixture models. Validation was performed using 2 data sets composed of patients with varying disease severity not used in the estimation and all available algorithms ranked on their performance.
RESULTS: None of the 5 existing algorithms offer an improvement in predictive accuracy over preferred algorithms from previous validation studies. Of the newly estimated algorithms, a 2-part beta model performed the best across the validation criteria and in data sets composed of patients with different levels of disease severity. Validation results did, however, vary widely between the 2 data sets, and the most accurate algorithm appears to depend on health state severity as the distribution of observed EQ-5D-3L values varies. Linear models performed better for patients in relatively good health, whereas beta, mixture, and response mapping models performed better for patients in worse health.
CONCLUSION: The most appropriate mapping algorithm to apply in practice may depend on the disease severity of the patient sample whose utility values are being predicted.

Entities:  

Keywords:  cancer; condition-specific non-preference-based measures; external validation; generic preference-based measures; quality of life; regression models

Mesh:

Year:  2018        PMID: 30226101     DOI: 10.1177/0272989X18797588

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  6 in total

1.  Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.

Authors:  Aurelie Meunier; Alexandra Soare; Helene Chevrou-Severac; Karl-Johan Myren; Tatsunori Murata; Louise Longworth
Journal:  Appl Health Econ Health Policy       Date:  2021-09-23       Impact factor: 3.686

2.  Health utilities for non-melanoma skin cancers and pre-cancerous lesions: A systematic review.

Authors:  C So; A E Cust; L G Gordon; R L Morton; K Canfell; P Ngo; M Dieng; K McLoughlin; C Watts
Journal:  Skin Health Dis       Date:  2021-06-04

3.  Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

Authors:  Matthew Walton; Ros Wade; Lindsay Claxton; Sahar Sharif-Hurst; Melissa Harden; Jai Patel; Ian Rowe; Robert Hodgson; Alison Eastwood
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

4.  Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets.

Authors:  Admassu N Lamu
Journal:  Eur J Health Econ       Date:  2020-04-16

5.  The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer.

Authors:  Joanne Gregory; Matthew Dyer; Christopher Hoyle; Helen Mann; Anthony J Hatswell
Journal:  Health Econ Rev       Date:  2020-04-21

6.  Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.

Authors:  Laura A Gray; Monica Hernandez Alava; Allan J Wailoo
Journal:  BMC Cancer       Date:  2021-11-18       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.